Active ingredientFutibatinibCat. No. P-F137-001CAS 1448169-71-8Family · Pharmaceutical analytical standards
Futibatinib
An irreversible inhibitor of the FGFR1-4 receptors, taken by mouth; approved in the United States in 2022 for intrahepatic cholangiocarcinoma, a bile duct cancer, with FGFR2 gene fusions or rearrangements. This family brings together the active ingredient.
Did you know?The suffix "-tinib" in its name is the one that international drug-naming rules reserve for tyrosine kinase inhibitors, enzymes that act as switches for cell growth.
Go to the active ingredient →Active ingredientFutibatinibCat. No. P-F137-001CAS 1448169-71-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.